Sentinel For Biosimilars? Biologics Post-Market Monitoring Is Focus Of New Consortium
Group of sponsors, insurers and health systems will draw on datasets of de-identified pharmacy and medical claims data to monitor effectiveness and safety of novel biologics and their corresponding biosimilars.
You may also be interested in...
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.